Pulse Biosciences reports 96% procedural success at 12 months for nPulse AF ablation study

PULSE BIOSCIENCES, INC.

100% procedural success at 6 months (75/75); 96% at 12 months (45/47) in first-in-human feasibility study.
Average procedure time 65 ± 28 min; left atrial dwell time 21 ± 13.3 min; fluoroscopy 9.8 ± 5.8 min.
Safety: 1.3% (2/150) subjects had a serious adverse event related to primary safety endpoint.
Data presented at AF Symposium 2026 by Dr. Vivek Reddy; 165 patients treated across 9 European sites.
Company plans to initiate pivotal IDE study in Europe and U.S. following these results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.